Rethinking health-related quality of life in cancer survivors: the role of tranexamic acid
Published
April 14, 2025
Paper ID
PAP-000023
Status
Published
DOI
10.65712/tmj.test000281
Advance Services
Abstract
Background: Practice around tranexamic acid varies widely between centres. Methods: We conducted a randomised controlled trial across 2 centres between 2019 and 2021. Results: Serious adverse events were rare and similar between groups. 1532 participants were included (median age 36 years). Conclusion: Future work should test tranexamic acid in a pragmatic multicentre trial.
Introduction
Practice around tranexamic acid varies widely between centres. Guidelines make only a weak recommendation on tranexamic acid.
health-related quality of life remains a leading cause of avoidable harm among cancer survivors. Guidelines make only a weak recommendation on tranexamic acid.
Guidelines make only a weak recommendation on tranexamic acid. Earlier studies of tranexamic acid were small or single-centre. Practice around tranexamic acid varies widely between centres.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was health-related quality of life, assessed blind to allocation. Missing data were handled with multiple imputation. Eligible participants were cancer survivors.
Missing data were handled with multiple imputation. The primary outcome was health-related quality of life, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. 1276 participants were included (median age 79 years). health-related quality of life occurred in 18% of the intervention group versus 20% of controls. health-related quality of life occurred in 12% of the intervention group versus 29% of controls.
The adjusted odds ratio was 0.75 (95% CI 0.33 to 0.74). The adjusted odds ratio was 0.62 (95% CI 0.48 to 0.88). The adjusted odds ratio was 0.72 (95% CI 0.38 to 0.98). health-related quality of life occurred in 7% of the intervention group versus 21% of controls.
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Control | 100 | 1 | 24.0 | 0.52 |
| Age < 65 | 461 | 45 | 38.8 | 0.80 |
| Age ≥ 65 | 555 | 83 | 25.9 | 0.87 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
health-related quality of life occurred in 19% of the intervention group versus 29% of controls. health-related quality of life occurred in 10% of the intervention group versus 28% of controls. health-related quality of life occurred in 9% of the intervention group versus 23% of controls.
Discussion
Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better health-related quality of life in cancer survivors.
Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better health-related quality of life in cancer survivors. Implementation will depend on staffing, cost and local protocols.
These findings suggest that tranexamic acid is associated with better health-related quality of life in cancer survivors. Strengths include the sample size and blinded outcome assessment. Future work should test tranexamic acid in a pragmatic multicentre trial.
Conclusions
Tranexamic acid should be considered for cancer survivors to improve health-related quality of life.
References
1. Zhang F, Kaur M, et al. Vitamin D supplementation and post-operative delirium. N Engl J Med. 2013;66(3):397-1063.
2. Rahman E, Moreau U, et al. Continuous glucose monitoring and falls. N Engl J Med. 2015;17(4):641-1786.
3. Mueller O, Lindqvist N, et al. Home-based cardiac rehabilitation and glycaemic control. BMJ. 2020;49(8):694-1373.
4. Kaur F, Novak C, et al. High-flow nasal oxygen and 30-day readmission. Crit Care Med. 2020;290(8):845-1394.
5. Volkov X, Silva B, et al. An antibiotic stewardship programme and length of stay. BMJ. 2009;75(8):53-1093.
Appendices
Ethics approval: IRB-8011.